Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. junior Avg
|
New words:
accessing, Acrivon, ADC, Addendum, affirmative, AppTec, architecture, Biotech, Bristol, calibration, category, chemotherapeutic, Chia, condensed, conjugate, Degron, delegated, DENALI, Diana, DPF, drove, Erroneously, fifty, flow, France, franchise, geopolitical, Germany, GluBio, Hausman, ID, IHC, immunohistochemistry, Immunome, ineffective, intragroup, Italy, JAK, Jan, Lackner, longevity, lunresertib, macroeconomic, MAMMOTH, mDOR, mobile, NeoX, noteworthy, PROC, PSOC, reacquire, regained, remeasured, Repare, resident, resigned, ruxolitinib, screen, settled, showcasing, Skvarka, sonrotoclax, Spain, Squibb, subgroup, sublet, subtenant, TETON, transmit, treatable, underway, uninsured, WuXi
Removed:
accumulation, ADME, aggressive, al, alteration, amplified, anticancer, arrest, Asia, Asian, bill, body, bone, carryover, classification, CLL, close, commerce, commonly, consummation, contact, count, coupled, depression, desire, diagnosed, diffuse, discontinued, disrupted, distancing, elimination, endometrial, entry, escalating, evergreen, evident, excretion, fallen, female, FL, follicular, gene, geographic, geographical, incurrence, inducing, induction, inform, inhibiting, intelligence, intracellular, ISA, lawfully, localization, locally, location, lung, lymphatic, lymphoma, macroglobulinemia, magnitude, malignant, MCL, MD, membrane, mitochondrial, mitochondrion, mm, monoclonal, MSA, mutation, myeloma, NHL, notable, NSCLC, occurring, overexpressed, PFS, PharmD, PhD, plasma, platelet, potent, PR, progressive, rash, receivable, regional, renamed, reproducible, resistance, restore, SCLC, select, serving, SLL, spiked, spread, stable, subsided, subtype, successor, surface, sustainable, tiered, toxicity, trajectory, transferring, treating, tyrosine, unconfirmed, uniform, vaccination, venture, Virginia, VPs, week, worker
Filing tables
Filing exhibits
Related press release
ZNTL similar filings
Filing view
External links
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in the following Registration Statements:
(1) Registration Statement (Form S-3 No. 333-255769) of Zentalis Pharmaceuticals, Inc.,
(2) Registration Statement (Form S-8 No. 333-237593) pertaining to the Zentalis
Pharmaceuticals, Inc. 2020 Incentive Award Plan,
(3) Registration Statement (Form S-8 No. 333-254506) pertaining to the Zentalis
Pharmaceuticals, Inc. 2020 Employee Stock Purchase Plan, and
(4) Registration Statement (Form S-8 No. 333-266702) pertaining to the Zentalis
Pharmaceuticals, Inc. 2020 Incentive Award Plan and the Zentalis Pharmaceuticals, Inc. 2022
Employment Inducement Incentive Award Plan;
of our reports dated February 27, 2024, with respect to the consolidated financial statements of Zentalis Pharmaceuticals, Inc., and the effectiveness of internal control over financial reporting of Zentalis Pharmaceuticals, Inc. included in this Annual Report (Form 10-K) of Zentalis Pharmaceuticals, Inc. for the year ended December 31, 2023.
/s/ Ernst & Young LLP
San Diego, California
February 27, 2024